Osteoporosis Market Insights, Epidemiology and Market Forecast–2028
DelveInsight’s ‘Osteoporosis—Market Insights, Epidemiology and Market Forecast–2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Osteoporosis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Osteoporosis from 2017 to 2028 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
Study Period: 2017–2028
Osteoporosis - Disease Understanding and Treatment Algorithm
Osteoporosis is defined as a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture. Osteoporosis is a bone disorder that increases a person’s risk of fracture due to low bone mineral density (BMD), impaired bone microarchitecture/mineralization, and/or decreased bone strength. Although osteoporosis is typically associated with women, it is also diagnosed in men, who account for an estimated one in five Americans who have osteoporosis or low bone mineral density (BMD). In addition to being the major cause of fractures in the older population, osteoporosis is also highly associated with people becoming bedridden, which can lead to serious complications. Osteoporosis can be divided into primary and secondary osteoporosis, wherein primary occurs with age and sex hormone deficiency and secondary osteoporosis occurs with several comorbid diseases and medications.
Osteoporosis can be diagnosed with a BMD test, bone mineral density (BMD) test, Fracture Risk Assessment Tool Model (FRAX), Vertebral imaging (Vertebral fracture assessment), Biochemical bone turnover marker (BTM), Quantitative Ultrasound (QUS), Quantitative Computed Tomography (QCT) and Peripheral QCT (pQCT) and Quality of DXA AND VFA. BMD tests can identify osteoporosis, determine the risk for fractures (broken bones), and measure response to osteoporosis treatment. The most widely recognized BMD test is a central dual-energy x-ray absorptiometry or central DXA test. Treatment of osteoporosis is strictly related to the severity of pathology. Initially, it is important to prevent fragility fractures with an active lifestyle and adequate nutritional supplements, including daily calcium and vitamin D intake, performing weight-bearing activities, avoiding or stopping smoking, and avoiding heavy alcohol consumption.
The DelveInsight Osteoporosis market report gives the thorough understanding of Osteoporosis by including details such as disease introduction, types of osteoporosis, causes of osteoporosis, symptoms, pathophysiology, pathology, risk factors, diagnosis, diagnostic biomarkers and differential diagnosis.
According to the International Osteoporosis Foundation (IOF), around the world, one in three women and one in five men aged fifty years and over are at risk of an osteoporotic fracture. In fact, an osteoporotic fracture is estimated to occur every 3 s. The most common fractures associated with osteoporosis occur at the hip, spine, and wrist. The likelihood of these fractures occurring, particularly at the hip and spine, increases with age in both women and men. IOF estimate that over 44 million people in the United States currently have osteoporosis. Approximately 30% of all postmenopausal women have osteoporosis in the United States and Europe. At least 40% of these women and 15–30% of men will sustain one or more fragility fractures in their remaining lifetime. An increased risk of 86% for any fracture has been demonstrated in people that have already sustained a fracture. Likewise, patients with a history of vertebral fracture have a 2.3-fold increased risk of future hip fracture and a 1.4-fold increase in the risk of distal forearm fracture.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Osteoporosis in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2028 for the following aspects:
The disease epidemiology covered in the report is segmented by:
• Prevalence of Osteoporosis
• Diagnosed Prevalent Population of Osteoporosis
• Gender-specific Prevalence of Osteoporosis
• Prevalence of Primary Osteoporosis
• Prevalence of Secondary Osteoporosis
• Incidence of Osteoporotic Fractures
• Osteoporosis-related comorbidities
As per a study conducted by Rausch et al. titled “We miss the opportunity: Pretreatment of osteoporosis in a German trauma center,” in Germany, the prevalence for osteoporosis in individuals of age 50 and above is estimated to be around 26% overall and 39% in women. In males, prevalence is estimated to be on a significantly lower level with 9.7% of the population over 50 years. Approximately 399 patients >60 years suffering low-energy-fractures of their spine, femur, humerus or forearm between 2014 and 2015 were recruited in a German trauma center. In about 21% (84 out of 399) of all patients, osteoporosis was diagnosed prior to current admission. Nearly 34% (136 out of 399) suffered a prior risk-fracture after age of 50. Also, 38% (19 out of 50) of these patients with fragility fractures and prior osteoporosis diagnosis received anti-osteoporotic medication. In case of corticoids taken by the patients, about 15.4% and 13.3% resulted in osteoporosis with prior and no prior fracture, respectively.
A clinical review study by the US Preventive Services Task Force Recommendation Statement projected that by 2020, approximately 12.3 million individuals in the United States older than 50 years are expected to have osteoporosis. Osteoporotic fractures, particularly hip fractures, are associated with limitations in ambulation, chronic pain and disability, loss of independence, and decreased quality of life, and 21–30% of patients who experience a hip fracture die within 1 year.
Osteoporosis Drug Chapters
This segment of the Osteoporosis report encloses the detailed analysis of the drugs that are expected to be launched in other regions. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the prevalent population of Osteoporosis and awareness of the disease. The overall dynamics of Osteoporosis market is anticipated to change in the coming years owing to the expected launch of emerging therapies that are already approved in specific regions but are expected to be launched in other regions as well. The major key players such as Amgen, Radius Health, and others will significantly increase the market during the forecast period (2019–2028).
Osteoporosis Market Outlook
Osteoporosis is a metabolic bone disease characterized by an imbalance between bone resorption and accrual, resulting in microarchitectural disruption, reduced bone mineral density (BMD), and skeletal fragility. Fragility fractures are common in the osteoporotic population and occur from forces, not ordinarily resulting in fracture. The most common sites are the vertebral column, hip and wrist; however, fragility fractures of the humerus, pelvis and ribs are not uncommon.
The treatment for Osteoporosis majorly includes pharmacological therapies to reduce the risk of fractures. Medications to treat osteoporosis are categorized as either antiresorptive (i.e., bisphosphonates, estrogen agonist/antagonists (EAAs), estrogens, calcitonin, and denosumab) or anabolic (i.e., teriparatide). Bisphosphonates are therefore effective agents to increase bone mineral density (BMD) at the spine and hip when used as primary prevention or as treatment in both men and women on long-term glucocorticoids.
The treatment of Osteoporosis mainly follows a mainstay treatment, i.e., pharmacological agents (bisphosphonates, hormone replacement therapy, selective estrogen receptor modulators, calcitonin, the 1–34 fragment of parathyroid hormone), calcium and vitamin D supplements, and calcitriol followed by surgery which is only preferred in case of severe osteoporosis cases in patients.
This segment gives a through detail of market trend of each therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Osteoporosis in the 7MM is expected to change from 2019–2028.
Osteoporosis Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017–2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Approval of therapies for Osteoporosis such as Evenity (Amgen; to be launched in Europe), Tymlos (Radius Health; to be launched in Europe), and other targeted therapies in the forecast period [2019–2028] will also create a positive impact on the Osteoporosis market.
Osteoporosis Report Insights
• Patient Population
• Therapeutic Approaches
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Osteoporosis Report Key Strengths
• 10-Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition
Osteoporosis Report Assessment
• Current Treatment Practices
• Unmet Needs
• Market Attractiveness
• Market Drivers and Barriers
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Osteoporosis market
• Organize sales and marketing efforts by identifying the best opportunities for Osteoporosis market
• To understand the future market competition in the Osteoporosis market.
Note: We understand the needs of the rapidly changing market and DelveInsight’s is helping the client by providing the most up to date Report. It usually takes 7-10 days to deliver this kind of Report.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook